www.acorda.com
Acorda Therapeutics is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system.
News
-
10/08/11
Acorda receives allowance for 2nd patent application of MS drug -
01/11/10
Acorda Therapeutics swings to profit in the third quarter on new launch of MS drug
Recent Sector News
-

Dow higher on home sales data, Dell earnings in focus
U.S. equity markets moved higher Tuesday afternoon as investors welcomed a report showing existing home sales surged in April for the first time since January.
-

Dow points to red on Japan downgrade, Apple, Facebook in focus
U.S. equity markets looked set to open lower Tuesday after Fitch Ratings cut Japan’s credit rating, citing rising public debt and slow deficit-reduction efforts.
-

Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-

Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-

Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
-

Snipp plans ambitious growth as mobile marketing takes off
Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
What do others think of Acorda Therapeutics
Investors interested in Acorda Therapeutics recently viewed
-
Epistem (AIM: EHP) Biotechnology company applying its expertise in epithelial stem cells -
Tissue Regenix Group (AIM: TRX) Delivering regenerative solutions -
Medgenics (AIM: MEDG) Developing "Biopump" technology for the treatment of chronic diseases -
NeoStem (NYSE AMEX: NBS) . -
Xenetic Biosciences (AIM: XEN) Innovators in development of drugs and vaccines



















